| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = -$11,763 ) |
| | 2022 | 2019 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44AR065886 | A novel immunotolerizing therapy for autoimmune vitiligo | 002 | 3 | NIH | 6/29/2022 | -$461 |
| | 2022 | 2019 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44AR065886 | A novel immunotolerizing therapy for autoimmune vitiligo | 000 | 3 | NIH | 3/24/2022 | $0 |
| | 2022 | 2018 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | U01ES024097 | Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur | 002 | 4 | NIH | 6/29/2022 | -$3,713 |
| | 2022 | 2018 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | U01ES024097 | Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur | 000 | 4 | NIH | 3/22/2022 | $0 |
| | 2022 | 2018 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44GM122095 | Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock | 001 | 2 | NIH | 6/29/2022 | -$7,589 |
| | 2022 | 2017 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | U01ES024097 | Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur | 001 | 3 | NIH | 6/29/2022 | $0 |
| | 2022 | 2017 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44GM100503 | Restoration of free radical homeostasis: novel therapy of septic shock | 000 | 3 | NIH | 3/15/2022 | $0 |
| | 2022 | 2017 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R44AR070686 | A pro-resolution lipid mediator for treatment of rheumatoid arthritis | 000 | 2 | NIH | 3/25/2022 | $0 |
| | 2022 | 2017 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44GM122095 | Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock | 000 | 1 | NIH | 6/29/2022 | $0 |
| | 2022 | 2017 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44AR065886 | A novel immunotolerizing therapy for autoimmune vitiligo | 001 | 2 | NIH | 6/29/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44AR065886 | A novel immunotolerizing therapy for autoimmune vitiligo | 000 | 3 | NIH | 11/9/2020 | $0 |
| | 2021 | 2017 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44GM100503 | Restoration of free radical homeostasis: novel therapy of septic shock | 000 | 3 | NIH | 6/12/2021 | $0 |
| | 2021 | 2017 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44AR070686 | A pro-resolution lipid mediator for treatment of rheumatoid arthritis | 000 | 2 | NIH | 11/9/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = -$24,138 ) |
| | 2020 | 2018 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44GM122095 | Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock | 000 | 2 | NIH | 9/9/2020 | $0 |
| | 2020 | 2015 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44HD082865 | Treatment of congenital heart disease associated pulmonary hypertension | 000 | 1 | NIH | 5/14/2020 | -$24,138 |
|
| Issue Date FY: 2019 ( Subtotal = $460,375 ) |
| | 2019 | 2019 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44AR065886 | A novel immunotolerizing therapy for autoimmune vitiligo | 000 | 3 | NIH | 9/9/2019 | $460,375 |
| | 2019 | 2017 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44GM100503 | Restoration of free radical homeostasis: novel therapy of septic shock | 000 | 3 | NIH | 6/4/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,522,547 ) |
| | 2018 | 2018 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | U01ES024097 | Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur | 000 | 4 | NIH | 8/28/2018 | $821,853 |
| | 2018 | 2018 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44GM122095 | Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock | 001 | 2 | NIH | 8/14/2018 | $719,358 |
| | 2018 | 2017 | SALZMAN GROUP, INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575 | DUKES | USA | R44GM122095 | Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock | 000 | 1 | NIH | 8/13/2018 | -$18,664 |
| | 2018 | 2017 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R44AR065886 | A novel immunotolerizing therapy for autoimmune vitiligo | 000 | 2 | NIH | 8/2/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $4,533,500 ) |
| | 2017 | 2017 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | U01ES024097 | Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur | 000 | 3 | NIH | 9/15/2017 | $781,772 |
| | 2017 | 2017 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R44GM100503 | Restoration of free radical homeostasis: novel therapy of septic shock | 000 | 3 | NIH | 7/14/2017 | $1,194,948 |
| | 2017 | 2017 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R44GM122095 | Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock | 000 | 1 | NIH | 4/3/2017 | $767,994 |
| | 2017 | 2017 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R44AR065886 | A novel immunotolerizing therapy for autoimmune vitiligo | 000 | 2 | NIH | 9/22/2017 | $1,039,086 |
| | 2017 | 2017 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R44AR070686 | A pro-resolution lipid mediator for treatment of rheumatoid arthritis | 000 | 2 | NIH | 9/12/2017 | $750,000 |
| | 2017 | 2015 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R44HD082865 | Treatment of congenital heart disease associated pulmonary hypertension | 000 | 1 | NIH | 8/7/2017 | $0 |
| | 2017 | 2014 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R43AR065886 | A Novel Immunotolerizing Therapy for Autoimmune Vitiligo | 000 | 1 | NIH | 3/7/2017 | $0 |
| | 2017 | 2014 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R44DK091972 | A potassium-ATP channel opener for prevention of contrast-induced nephropathy | 000 | 2 | NIH | 3/15/2017 | -$299 |
| | 2017 | 2014 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R43EY024806 | A novel prodrug for K+-ATP channel activation in the glaucomatous eye | 000 | 1 | NIH | 1/22/2017 | $0 |
| | 2017 | 2014 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | R43NS081799 | Bifunctional potassium-ATP channel opener and redox catalyst for therapy of spina | 000 | 1 | NIH | 2/21/2017 | $0 |
| | 2017 | 2014 | RADIKAL THERAPEUTICS INC. | 8 SOLVIVA RD | WEST TISBURY | MA | 02575-0000 | DUKES | USA | U01ES021154 | Multifunctional therapeutics for treatment of acute chlorine inhalational injury | 000 | 4 | NIH | 9/28/2017 | -$1 |
|
| Issue Date FY: 2016 ( Subtotal = $1,998,631 ) |
| | 2016 | 2016 | RADIKAL THERAPEUTICS INC | 8 SOLVIVA ROAD | WEST TISBURY | MA | 02575 | DUKES | USA | R44AR070686 | A pro-resolution lipid mediator for treatment of rheumatoid arthritis | 000 | 1 | NIH | 8/31/2016 | $724,857 |
| | 2016 | 2016 | RADIKAL THERAPEUTICS INC | 8 SOLVIVA ROAD | WEST TISBURY | MA | 02575 | DUKES | USA | R44GM100503 | Restoration of free radical homeostasis: novel therapy of septic shock | 000 | 2 | NIH | 9/1/2016 | $1,248,631 |
| | 2016 | 2016 | RADIKAL THERAPEUTICS INC | 8 SOLVIVA ROAD | WEST TISBURY | MA | 02575 | DUKES | USA | R44AR070686 | A pro-resolution lipid mediator for treatment of rheumatoid arthritis | 001 | 1 | NIH | 9/1/2016 | $25,143 |
| | 2016 | 2015 | RADIKAL THERAPEUTICS INC | 8 SOLVIVA ROAD | WEST TISBURY | MA | 02575 | DUKES | USA | U01ES024097 | Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur | 000 | 2 | NIH | 6/30/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $2,310,596 ) |
| | 2015 | 2015 | RADIKAL THERAPEUTICS INC | 8 SOLVIVA ROAD | WEST TISBURY | MA | 02575 | DUKES | USA | R44HD082865 | Treatment of congenital heart disease associated pulmonary hypertension | 000 | 1 | NIH | 3/31/2015 | $1,500,000 |
| | 2015 | 2015 | RADIKAL THERAPEUTICS INC | 8 SOLVIVA ROAD | WEST TISBURY | MA | 02575 | DUKES | USA | U01ES024097 | Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur | 000 | 2 | NIH | 9/17/2015 | $810,596 |
| | 2015 | 2014 | RADIKAL THERAPEUTICS INC | 8 SOLVIVA ROAD | WEST TISBURY | MA | 02575 | DUKES | USA | U01ES021154 | Multifunctional therapeutics for treatment of acute chlorine inhalational injury | 000 | 4 | NIH | 8/21/2015 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $3,629,060 ) (Continued on the next page) |
| | 2014 | 2014 | RADIKAL THERAPEUTICS INC | 8 SOLVIVA ROAD | WEST TISBURY | MA | 02575 | DUKES | USA | U01ES024097 | Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur | 001 | 1 | NIH | 9/22/2014 | -$774,459 |
| | 2014 | 2014 | RADIKAL THERAPEUTICS INC | 8 SOLVIVA ROAD | WEST TISBURY | MA | 02575 | DUKES | USA | U01ES024097 | Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur | 001 | 1 | NIH | 9/22/2014 | $774,459 |
|
